ClinicalTrials.gg
Active, not recruitingNCT06225596Updated Oct 29, 2026

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

A Phase 2 interventional study of Zelenectide pevedotin and Zelenectide pevedotin in Metastatic Urothelial Cancer, sponsored by BicycleTx Limited. Active, not recruiting at 102 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by BicycleTx Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 137 studies in Urinary Bladder Neoplasms with a site in Spain — 25 open to participants now, 53 under way, 16 of them phase 3. Urinary Bladder Neoplasms · Spain.

Planned enrollment
34th of 127
375 · median 175
Started
2024
with 6 others
Phase 2
43 of 137
9 open now
Primary completion
2028-03
later than 38 of 52 live
Registered
117th of 137
by date

Among the 137 studies in Urinary Bladder Neoplasms with a site in Spain, this one is the 34th largest by planned enrollment of the 127 interventional ones that give a count, is one of 7 that started in 2024, is one of 43 in phase 2, reaches primary completion later than 38 of the 52 other live ones, and was the 117th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

25 of the 137 studies in Urinary Bladder Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Urinary Bladder Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

This is a global, multicenter, randomized, open-label study. The main objective of the study is to measure the clinical activity and safety of zelenectide pevedotin formally BT8009, in combination with pembrolizumab versus chemotherapy, and as monotherapy in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection for zelenectide pevedotin and is comprised of 2 cohorts. Cohort 1 will include participants who have not received any prior systemic therapy for locally advanced or metastatic UC and are eligible to receive platinum-based chemotherapy, whereas Cohort 2 will include participants who have received ≥ 1 prior systemic therapy for locally advanced or metastatic UC.

03

Conditions studied

  • Metastatic Urothelial Cancer

Keywords

  • Metastatic Urothelial Cancer
  • BT8009
  • Bladder cancer
  • Pembrolizumab
  • Chemotherapy
  • Avelumab
  • Zelenectide pevedotin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • ≥ 12 weeks.
  • as defined by v1.1.
  • or cytologically confirmed locally advanced (unresectable) or UC of the renal pelvis, ureter, bladder, or urethra.
  • Archival or fresh tumor tissue comprising primary or metastatic UC should be available for submission to central laboratory.
  • Negative pregnancy test for women of (WOCBP) (negative serum test at Screening and negative urine or serum test within 72 hours prior to the first dose).
  • Cohort 1: Previously Untreated: Eligible to receive platinum-based chemotherapy (either cisplatin- or carboplatin-based chemotherapy based on Investigator decision.
  • Cohort 1: Participants must not have received prior systemic therapy for locally advanced or metastatic UC with the following exceptions:

    1. Prior local intravesical chemotherapy, local surgery when full resection is not achieved, local immunotherapy, and radiotherapy are permitted if completed at least 4 weeks prior to the initiation of study treatment and all acute toxicities have resolved.
    2. Prior /adjuvant chemotherapy or monomethyl auristatin E (MMAE)-based therapy with recurrence >12 months from completion of therapy.
    3. Prior neoadjuvant/adjuvant therapy with recurrence >12 months from completion of therapy.
  • Cohort 2: Previously Treated: Participants must have received ≥ 1 prior systemic treatment for locally advanced or metastatic UC. This includes neoadjuvant/adjuvant platinum-based chemotherapy if recurrence occurred within 12 months of completing therapy.
  • Cohort 2: Progression or recurrence of UC during or following receipt of most recent therapy.

Key Exclusion Criteria:

  • Active keratitis or corneal ulcerations.
  • Requirement, while receiving study medications, for treatment with strong inhibitors or strong inducers of human cytochrome P450 3A () or inhibitors of P-glycoprotein (P-gp) including herbal- or food-based inhibitors.
  • Any condition requiring current treatment with high dose (> 10 mg daily prednisone or equivalent).
  • Known or allergy to any of the ingredients of any of the study interventions, or to MMAE.
  • Has not adequately recovered from recent major surgery (excluding placement of vascular access).
  • Receipt of live or attenuated vaccine within 30 days of first dose.
  • Cohort 1: Previously Untreated: Prior treatment with a checkpoint inhibitor (CPI) for any other within the last 12 months.
  • Cohort 2: Previously Treated: Received more than 1 prior platinum-based chemotherapy regimen for locally advanced or metastatic UC. This includes neoadjuvant/adjuvant platinum-based chemotherapy if recurrence occurred within 12 months of completing therapy.
  • Cohort 2: Prior treatment with enfortumab vedotin or any other MMAE-based therapy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Zelenectide pevedotin Arm 1

    Participants will receive zelenectide pevedotin and a standard dose of pembrolizumab.

    Drug: Zelenectide pevedotin · Drug: Pembrolizumab

  • Experimental
    Cohort 1: Zelenectide pevedotin Arm 2

    Participants will receive zelenectide pevedotin and a standard dose of pembrolizumab.

    Drug: Zelenectide pevedotin · Drug: Pembrolizumab

  • Active comparator
    Cohort 1: Arm 3

    Participants will receive Platinum-based combination chemotherapy +/- avelumab maintenance

    Drug: Gemcitabine + cisplatin Or carboplatin · Drug: Avelumab

  • Experimental
    Cohort 2: Zelenectide pevedotin Arm 1

    Participants will receive zelenectide pevedotin.

    Drug: Zelenectide pevedotin

  • Experimental
    Cohort 2: Zelenectide pevedotin Arm 2

    Participants will receive zelenectide pevedotin.

    Drug: Zelenectide pevedotin

Interventions

  • Participants will receive zelenectide pevedotin on Days 1, 8, and 15 of every 21-day cycle.

    Also known as: BT8009

  • Participants will receive zelenectide pevedotin on Days 1 and 8 of every 21-day cycle.

    Also known as: BT8009

  • Participants will receive Pembrolizumab on Day 1 of every 21-day cycle. Pembrolizumab infusion will be started 30 minutes following the completion of the zelenectide pevedotin infusion.

  • DrugGemcitabine + cisplatin Or carboplatin

    Participants will receive Gemcitabine on Days 1 and 8 of every 21-day cycle plus cisplatin Or carboplatin on Day 1 of every 21-day cycle.

  • After 4-6 cycles of Gemcitabine + Cisplatin or Carboplatin participants will receive maintenance Avelumab, if clinically indicated, on Days 1 and 15 each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Cohort 1: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST v1.1) by blinded central independent review (BICR) of optimal dose zelenectide pevedotin with pembrolizumab versus chemotherapy

    The time from randomization to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  2. Cohort 2: PFS per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimen

    The time from randomization to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  3. Cohort 2: Objective response rate (ORR) per RECIST v1.1 assessed by BICR of zelenectide pevedotin monotherapy in each treatment regimen

    Time frame: Up to approximately 4 years

Secondary outcomes

  1. Cohort 1: PFS per RECIST v1.1 assessed by BICR of zelenectide pevedotin combined treatment arms versus chemotherapy

    The time from randomization to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  2. Cohort 1: ORR per RECIST v1.1 assessed by BICR of optimal dose zelenectide pevedotin in combination with pembrolizumab versus chemotherapy.

    Time frame: Up to approximately 4 years

  3. Cohort 1: ORR per RECIST v1.1 assessed by BICR of zelenectide pevedotin combined treatment arms versus chemotherapy

    Time frame: Up to approximately 4 years

  4. Cohort 1: Overall survival (OS) rate of optimal dose zelenectide pevedotin in combination with pembrolizumab versus chemotherapy

    The time from randomization to date of death from any cause.

    Time frame: Up to approximately 4 years

  5. Cohort 1: Duration of response (DoR) per RECIST v1.1 assessed by BICR of optimal dose of zelenectide pevedotin in combination with pembrolizumab

    The time from time of first documentation of objective response that is subsequently confirmed to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  6. Cohort 1: Disease control rate (DCR) per RECIST v1.1 assessed by BICR of optimal dose of zelenectide pevedotin in combination with pembrolizumab

    The time from randomization to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  7. Cohort 1: PFS per RECIST v1.1 assessed by BICR of unselected zelenectide pevedotin dose in combination with pembrolizumab

    The time from randomization to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  8. Cohort 1: OS rate of zelenectide pevedotin combined treatment arms in combination with pembrolizumab versus chemotherapy

    The time from randomization to date of death from any cause

    Time frame: Up to approximately 4 years

  9. Cohort 2: DoR per RECIST v1.1 assessed by BICR in each treatment regimen

    The time from time of first documentation of objective response that is subsequently confirmed to date of first documentation of disease progression or death.

    Time frame: Up to approximately 4 years

  10. Cohort 2: DCR per RECIST v1.1 assessed by BICR in each treatment regimen

    The time from cycle 1 Day 1 to date of first documentation of disease progression or death

    Time frame: Up to approximately 4 years

  11. Cohort 2: OS rate in each treatment regimen

    The time from randomization to date of death from any cause

    Time frame: Up to approximately 4 years

  12. Cohorts 1 and 2: Safety and tolerability of each treatment regimen

    Safety will be reported as incidence, severity, seriousness, relationship to study and types of adverse events

    Time frame: Until 30 days post last dose, up to approximately 4 years

  13. Cohorts 1 and 2: Exposure-efficacy relationships for zelenectide pevedotin area under the plasma concentration-time curve (AUC)

    Quantitative modeling of the association between measured zelenectide pevedotin pharmacokinetic (PK) parameter (AUC) and ORR.

    Time frame: Until the end of treatment, up to approximately 4 years

  14. Cohorts 1 and 2: Exposure-efficacy relationships for zelenectide pevedotin AUC

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (AUC) and PFS.

    Time frame: Until the end of treatment, up to approximately 4 years

  15. Cohorts 1 and 2: Exposure-efficacy relationships for monomethyl auristatin (MMAE) AUC

    Quantitative modeling of the association between measured MMAE PK parameter (AUC) and ORR.

    Time frame: Until the end of treatment, up to approximately 4 years

  16. Cohorts 1 and 2: Exposure-efficacy relationships for MMAE AUC

    Quantitative modeling of the association between measured MMAE PK parameter (AUC) and PFS.

    Time frame: Until the end of treatment, up to approximately 4 years

  17. Cohorts 1 and 2: Exposure-efficacy relationships for zelenectide pevedotin maximum plasma concentration (Cmax)

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (Cmax) and ORR.

    Time frame: Until the end of treatment, up to approximately 4 years

  18. Cohorts 1 and 2: Exposure-efficacy relationships for zelenectide pevedotin Cmax

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (Cmax) and PFS.

    Time frame: Until the end of treatment, up to approximately 4 years

  19. Cohorts 1 and 2: Exposure-efficacy relationships for MMAE Cmax

    Quantitative modeling of the association between measured MMAE PK parameter (Cmax) and ORR.

    Time frame: Until the end of treatment, up to approximately 4 years

  20. Cohorts 1 and 2: Exposure-efficacy relationships for MMAE Cmax

    Quantitative modeling of the association between measured MMAE PK parameter (Cmax) and PFS.

    Time frame: Until the end of treatment, up to approximately 4 years

  21. Cohorts 1 and 2: Exposure-efficacy relationships for zelenectide pevedotin average plasma concentration (Cavg)

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (Cavg) and ORR.

    Time frame: Until the end of treatment, up to approximately 4 years

  22. Cohorts 1 and 2: Exposure-efficacy relationships for zelenectide pevedotin Cavg

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (Cavg) and PFS.

    Time frame: Until the end of treatment, up to approximately 4 years

  23. Cohorts 1 and 2: Exposure-efficacy relationships for MMAE Cavg

    Quantitative modeling of the association between measured MMAE PK parameter (Cavg) and ORR.

    Time frame: Until the end of treatment, up to approximately 4 years

  24. Cohorts 1 and 2: Exposure-efficacy relationships for MMAE Cavg

    Quantitative modeling of the association between measured MMAE PK parameter (Cavg) and PFS.

    Time frame: Until the end of treatment, up to approximately 4 years

  25. Cohorts 1 and 2: Exposure-safety relationships for zelenectide pevedotin AUC

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (AUC) and clinical safety, measured by incidence of most frequent or relevant treatment emergent adverse events and treatment related adverse events

    Time frame: Until the end of treatment, up to approximately 4 years

  26. Cohorts 1 and 2: Exposure-safety relationships for MMAE AUC

    Quantitative modeling of the association between measured MMAE PK parameter (AUC) and clinical safety, measured by incidence of most frequent or relevant treatment emergent adverse events and treatment related adverse events.

    Time frame: Until the end of treatment, up to approximately 4 years

  27. Cohorts 1 and 2: Exposure-safety relationships for zelenectide pevedotin Cmax

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (Cmax) and clinical safety, measured by incidence of most frequent or relevant treatment emergent adverse events and treatment related adverse events.

    Time frame: Until the end of treatment, up to approximately 4 years

  28. Cohorts 1 and 2: Exposure-safety relationships for MMAE Cmax

    Quantitative modeling of the association between measured MMAE PK parameter (Cmax) and clinical safety, measured by incidence of most frequent or relevant treatment emergent adverse events and treatment related adverse events.

    Time frame: Until the end of treatment, up to approximately 4 years

  29. Cohorts 1 and 2: Exposure-safety relationships for zelenectide pevedotin Cavg

    Quantitative modeling of the association between measured zelenectide pevedotin PK parameter (Cavg) and clinical safety, measured by incidence of most frequent or relevant treatment emergent adverse events and treatment related adverse events.

    Time frame: Until the end of treatment, up to approximately 4 years

  30. Exposure-safety relationships for MMAE Cavg

    Quantitative modeling of the association between measured MMAE PK parameter (Cavg) and clinical safety, measured by incidence of most frequent or relevant treatment emergent adverse events and treatment related adverse events.

    Time frame: Until the end of treatment, up to approximately 4 years

07

Study locations

102 sites

Showing the first 100 of 102 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2028, 50 months after the start.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 50 months is above that.

Counting every sponsor, half of 194 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Jan 26, 2024
StartActual
Jan 24, 2024
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06225596
Lead sponsor
BicycleTx Limited
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Jan 24, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelenectide pevedotin

Start the discussion